COVID-19时代的肝脏：肝病学家应该知道的

StephenW

Review
Ann Hepatol

. 2020 May 18.
doi: 10.1016/j.aohep.2020.05.001. Online ahead of print.
The Liver in Times of COVID-19: What Hepatologists Should Know
Ezequiel Ridruejo  1   2   3 , Alejandro Soza  3   4
Affiliations

    PMID: 32425991 PMCID: PMC7233236 DOI: 10.1016/j.aohep.2020.05.001

Abstract

The ongoing pandemic of coronavirus disease 2019 (COVID-19) pandemic poses a serious threat to healthcare systems globally. Information regarding to the how the infection affects the liver and relevance of pre-existing liver disease as a risk factor for acquiring the infection or having a severe disease are still scarce. Also, considerations to be considered in liver transplant patients or those having hepatocellular carcinoma or are under immunosuppressive therapy are being matter of analysis as information is being generated. Different treatments for COVID-19 are currently under study some of which may be associated to hepatotoxicity. In the present review we discuss current data on the COVID-19 and liver aiming to provide hepatologists with updated information to face this pandemic.

Keywords: ACE2, Angiotensin-converting enzyme 2; ALT, alanine aminotransferase; ARDS, acute respiratory distress syndrome; AST, aspartate aminotransferase; CDC, Centers for Disease Control and Prevention; COVID-19, coronavirus disease 2019; EVD, Ebola virus disease; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; ICU, intensive care unit; IL, interleukin; ILCA, International Liver Cancer Association; MAFLD, metabolic associated fatty liver diseases; NAFLD, non-alcoholic fatty liver disease; NIDDK, National Institute of Diabetes and Digestive and Kidney Diseases; RdRp, RNA-dependent RNA polymerase; SARS-CoV-2; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TNF-α, tumor necrosis factor-alpha; WHO, World Health Organization; coronavirus; immunosuppression; liver disease; nsp, non-structural proteins; transplantation, cirrhosis.

© 2020 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U.
Publication types

    Review

StephenW

评论
安·赫帕托尔

。 2020年5月18日
doi：10.1016 / j.aohep.2020.05.001。在线印刷。
COVID-19时代的肝脏：肝病学家应该知道的
Ezequiel Ridruejo 1 2 3，亚历杭德罗·索萨3 4
隶属关系

    PMID：32425991 PMCID：PMC7233236 DOI：10.1016 / j.aohep.2020.05.001

抽象

持续的2019年冠状病毒病大流行（COVID-19）大流行对全球医疗系统构成了严重威胁。关于感染如何影响肝脏以及先前存在的肝脏疾病作为获得感染或患有严重疾病的危险因素的相关性的信息仍然很少。同样，随着信息的产生，在肝移植患者或患有肝细胞癌或正在接受免疫抑制治疗的患者中考虑的考虑因素也正在进行分析。目前正在研究COVID-19的不同治疗方法，其中一些可能与肝毒性有关。在本综述中，我们讨论了有关COVID-19和肝脏的最新数据，旨在为肝病医生提供面对这一大流行病的最新信息。

关键字：ACE2，血管紧张素转化酶2； ALT，丙氨酸转氨酶； ARDS，急性呼吸窘迫综合征； AST，天冬氨酸转氨酶； CDC，疾病控制和预防中心； COVID-19，冠状病毒病2019; EVD，埃博拉病毒病； HBV，乙肝病毒； HCC，肝细胞癌；重症监护病房，重症监护病房； IL，白介素； ILCA，国际肝癌协会； MAFLD，与代谢有关的脂肪肝疾病； NAFLD，非酒精性脂肪肝； NIDDK，美国糖尿病与消化及肾脏疾病研究所； RdRp，RNA依赖性RNA聚合酶； SARS-CoV-2; SARS-CoV-2，严重急性呼吸系统综合症冠状病毒2； TNF-α，肿瘤坏死因子-α；世卫组织，世界卫生组织；新冠病毒;免疫抑制肝病; nsp，非结构蛋白；移植，肝硬化。

©2020FundaciónClínicaMédicaSur，A.C.由ElsevierEspaña，S.L.U发布。
出版类型

    评论

StephenW

https://www.sciencedirect.com/sc ... 20300430?via%3Dihub